1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Mark M. Awad(Memorial Sloan Kettering Cancer Center), P. Rietschel(Regeneron (United States)), F. Seebach(Regeneron (United States)), Yingying Hao(Harbin Medical University), Patrick T. Bruck(BioNTech (Germany)), S. Li(Regeneron (United States)), Priscila Gonçalves(The Barbara Ann Karmanos Cancer Institute), M. Kaul(Regeneron (United States))
Cited by 4
Related Papers
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
|Nature Genetics|2018|701
<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression
|Journal of Clinical Oncology|2016|687
Estimating Survival in Patients With Lung Cancer and Brain Metastases
|JAMA Oncology|2016|655
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
|Clinical Cancer Research|2018|445
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
|Nature Medicine|2020|399